Watch KYTX. Know when insiders buy.
One email the day a filing lands. Free.
KYTX
Kyverna Therapeutics, Inc.
7.13
+0.09 +1.28%
USD · close Sep 18
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
51
WATCH · shorts 51
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $440.9MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$152.6MNET CASH $6.9M52W 5.41 – 11.25SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$39.6M | −$38.3M | — | -0.63 | −$40.3M | — | — | Aug 11 |
| Q1 2026 · Mar 31 | — | — | — | −$41.4M | −$39.7M | — | -0.66 | −$41.6M | — | — | Aug 11 |
| Q4 2025 · Dec 31derived | — | — | — | −$39.3M | −$37.8M | — | -0.79 | −$33.5M | −$1K | −$33.5M | Mar 26 |
| Q3 2025 · Sep 30 | — | — | — | −$38.7M | −$36.8M | — | -0.85 | −$43.3M | $2K | −$43.3M | Nov 12 |
| Q2 2025 · Jun 30 | — | — | — | −$44.4M | −$42.1M | — | -0.97 | −$31.9M | $4K | −$32M | Aug 11 |
| Q1 2025 · Mar 31 | — | — | — | −$47.4M | −$44.6M | — | -1.03 | −$44.9M | $0 | −$44.9M | Aug 11 |
| Q4 2024 · Dec 31derived | — | — | — | −$41M | −$37.5M | — | -0.88 | −$37.1M | $532K | −$37.6M | Mar 26 |
| Q3 2024 · Sep 30 | — | — | — | −$38.8M | −$34.5M | — | -0.80 | −$27.5M | $102K | −$27.6M | Nov 12 |
| Q2 2024 · Jun 30 | — | — | — | −$33.4M | −$28.8M | — | -0.67 | −$24.2M | $1M | −$25.2M | Nov 12 |
| Q1 2024 · Mar 31 | — | — | — | −$29.4M | −$26.7M | — | -1.12 | −$25.5M | $543K | −$26.1M | Nov 12 |
| Q4 2023 · Dec 31derived | — | — | — | −$21.4M | −$20.7M | — | -26.86 | −$18.6M | $334K | −$18.9M | Mar 27 |
| Q3 2023 · Sep 30 | — | — | — | −$16.3M | −$15.5M | — | -23.27 | −$11.1M | $256K | −$11.4M | Nov 13 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$169.8M | −$161.3M | — | -3.64 | −$153.7M | $5K | −$153.7M | — | — |
| FY2024 · to Dec 31 | — | — | −$142.6M | −$127.5M | — | -3.33 | −$114.3M | $2.2M | −$116.5M | — | — |
| FY2023 · to Dec 31 | — | — | −$62.4M | −$60.4M | — | -89.61 | −$52.4M | $621K | −$53M | — | — |
Every number comes from Kyverna Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.